{"id":40992,"date":"2013-10-25T23:19:23","date_gmt":"2013-10-26T03:19:23","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=40992"},"modified":"2013-10-26T01:50:24","modified_gmt":"2013-10-26T05:50:24","slug":"stories-like-the-one-told-here","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2013\/10\/25\/stories-like-the-one-told-here\/","title":{"rendered":"stories like the one told here…"},"content":{"rendered":"
\n
\n
Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder<\/a><\/div>\n
by Steven J. Garlow<\/font><\/strong>, Becky Kinkead<\/font><\/strong>, Michael E. Thase , Lewis L. Judd, A. John Rush, Kimberly A. Yonkers , David J. Kupfer, Ellen Frank, Pamela J. Schettler<\/font><\/strong>, and Mark Hyman Rapaport<\/font><\/strong><\/div>\n
Journal of Psychiatric Research<\/font><\/strong> 2013<\/font><\/strong> 47:1199-1203.<\/div>\n

<\/p>\n

Objective<\/font><\/strong><\/u>: Some reports suggest an increase in suicide ideations and behaviors in patients treated with antidepressants. This is an analysis of the impact of fluoxetine on suicide ideations in outpatients with minor depressive disorder. <\/div>\n
Methods<\/font><\/strong><\/u>: Research subjects were adult outpatients with minor depressive disorder [N = 162], who received fluoxetine or placebo in a prospective, 12-week, double-blind randomized trial. The research participants were evaluated weekly with standard rating scales that included four suicide-related items: <\/div>\n
• item 3 of the Hamilton Rating Scale for Depression [HRSD], <\/div>\n
• item 18 of Inventory of Depressive Symptomatology [IDS-C], and <\/div>\n
• items 15 and 59 of the Hopkins Symptom Checklist [SCL-90].<\/div>\n
Clinically significant intensification of suicide ideation was defined as an increase of 2 points on any of these items. <\/div>\n
Results<\/font><\/strong><\/u>: Overall 60\/162 subjects [37%] had an increase of 1 point during treatment and 17\/162 [10.5%] of 2 points on at least one suicide item, with 12\/81 [14.8%] placebo and 5\/81 [6.2%] fluoxetine-treated subjects having a 2 point gain. Of the study participants with baseline suicide ideation, 9\/22 [40.9%] placebo and 3\/24 [12.5%] fluoxetine treated had 2 point increase [p = 0.04]. Survival analysis revealed that subjects on placebo were significantly more likely [p = 0.050] to experience a 2 point increase on one or more item, a difference that emerged early and continued throughout the 12-week trial. <\/div>\n
Conclusions<\/font><\/strong><\/u>: Compared to placebo, fluoxetine was not associated with a clinically significant increase in suicide ideation among adults with minor depressive disorder during 12 weeks of treatment.<\/div>\n

<\/p>\n

The authors would like to thank John Plewes MD<\/font><\/strong> for his enthusiastic encouragement and support. This study was supported in part by NIMH grants MH-30914, MH-49671, MH-30915, MH-53799, and MH-01648-01; the Roher Fund of the University of California, San Diego; and an unrestricted investigator-initiated contract from Eli Lilly & Co.<\/font><\/strong><\/em><\/div>\n<\/blockquote>\n
This post is not an attempt to vet this paper which is just another retrospective attempt to undermine the FDA Black Box warning about suicidality with SSRIs. That take down is in a Letter to the Editor by Drs. Marc B. Stone and Tarek A. Hammad, authors of the meta-analyses that lead to the warnings [Journal of Psychiatric Research<\/font><\/strong>.<\/a> 2013 Sep 30. Epub ahead of print]. It’s behind a paywall, but it’s definitive. However, the authors of this article themselves do a reasonable job of undermining the conclusions in that little read paragraph that ends most articles – limitations<\/em>: <\/div>\n
\n
"There are certain limitations to this study that need to be considered when evaluating the results. This is a secondary analysis of an efficacy trial that was not specifically designed or powered to address the potential relationship between fluoxetine treatment and suicide ideation. The total number of subjects in the subgroups who experienced a worsening of suicide ideation is small so the study may be under-powered to fully evaluate this effect. Another potential limitation is the focus on rating scale-based assessment of suicide risk, with no other outcome measures such as adverse event reports, as has been employed in other analyses of this question… Patients with HRSD item 3 score or IDS-C item 18 above were excluded as were those considered at high suicide risk by the investigators during screening. Therefore, the study sample may have been depleted of those most at risk to experience antidepressant-induced treatment emergent suicide ideations and behaviors and so underestimate this outcome. A final consideration is that this trial included adults with minor depressive disorder, with mean age of 43.5 years so the results cannot be extrapolated to adolescents and young adults…"<\/div>\n<\/blockquote>\n
I thought this article was an odd offering, an anachronism. It used rating scale numbers to assess suicidality, a long debunked methodology. On the surface, it was Emory University generated [four authors in blue<\/font><\/strong>], but it carried some hints to its history [the other authors, the journal that published it with editor Alan Schatzberg and a number of other veterans of Senator Grassley’s investigation as Assistant Editors, the mention of Eli Lilly<\/font><\/strong> funding of the original study,  the hat-tip to John Plewes<\/font><\/strong> who is a long-time Lilly employee with a string of anti-Black-Box articles of his own, and Minor Depressive Disorder – a non-diagnosis from a long time back]. So I thought I’d take a look at the original study itself. Here’s a time-line:<\/div>\n
<\/div>\n
The source was a clinical trial conceived by Eli Lilly<\/font><\/strong> in 1992<\/font><\/strong>, a long twenty years ago. It was during the lead-in to the DSM-IV Revision<\/font><\/strong> [1994], and there was a move afoot to include Minor Depressive Disorder<\/a> [miD<\/font><\/strong>] in the manual. So the clinical trial was designed to both characterize miD<\/font><\/strong> and demonstrate the efficacy of Prozac® in the not-yet-disorder. Population surveys had documented a very large cohort of depressed people who didn’t meet rigid Major Depressive Disorder<\/font><\/strong> [MDD<\/font><\/strong>] criteria – a desirable market. Then, as now, people were struggling with the DSM way of defining Disorders. miD<\/font><\/strong> didn’t make it into the manual. At that time, the question of suicidality from SSRIs was in its infancy, and an FDA hearing<\/a> in 1991 had just exonerated them. The clinical trial itself was between 1994 and 1996. I have no information that explains why the publication of the results from this trial had such a long lag time. Perhaps, with miD<\/font><\/strong> not making the DSM-IV, it didn’t matter so much after all, this was the heyday of the SSRIs, so they were being prescribed for most symptomatic depressions anyway. Maybe they were waiting for the DSM-5 Task Force to be formed [author David Kupfer lead that effort] for another try. Another reason, Lilly’s approval for Cymbalta® in 2004 is another possibility. But I don’t know the answer for sure. In any case, there were two articles published – one about miD<\/font><\/strong> and one about using Prozac® for treatment of miD<\/font><\/strong>.<\/div>\n
\n
A Descriptive Analysis of Minor Depression<\/a><\/div>\n
by Mark Hyman Rapaport, M.D.<\/font><\/strong>; Lewis L. Judd, M.D.; Pamela J. Schettler, Ph.D.<\/font><\/strong>; Kimberly Ann Yonkers, M.D.; Michael E. Thase, M.D.; David J. Kupfer, M.D.; Ellen Frank, Ph.D.; John M. Plewes, M.D.<\/font><\/strong>; Gary D. Tollefson, M.D., Ph.D.<\/font><\/strong>; and A. John Rush, M.D.<\/div>\n
American Journal of Psychiatry<\/font><\/strong> 2002<\/font><\/strong> 159:637-643
[full text on-line<\/a>]<\/div>\n

<\/p>\n

OBJECTIVE<\/font><\/strong><\/u>: The authors provide a detailed clinical description of minor depression: its symptoms, level of disability, stability, and relationship to patient and family history of major depressive disorder. <\/div>\n
METHOD<\/font><\/strong><\/u>: Rigorous criteria for minor depression, including functional disability, were used to identify 226 individuals for a three-phase treatment study. This report presents data obtained on that study group during the first study phase, a 4-week placebo lead-in period. <\/div>\n
RESULTS<\/font><\/strong><\/u>: One hundred sixty-two subjects [72% of the initial study group] remained in the study for 4 weeks and continued to meet criteria for minor depression. Minor depression in these subjects was primarily characterized by mood and cognitive symptoms, not the classical neurovegetative signs and symptoms of depression. Approximately one-third of the subjects with minor depression had a past history of major depressive disorder, and nearly half had a family history of unipolar depressive disorder; however, neither factor affected the severity or quality of minor depressive symptoms. <\/div>\n
CONCLUSIONS<\/font><\/strong><\/u>: These data suggest that:<\/div>\n
[1] minor depression is not evanescent; <\/div>\n
[2] minor depression is characterized by mood and cognitive symptoms rather than neurovegetative symptoms; <\/div>\n
[3] minor depression may occur either independently of a lifetime history of major depressive disorder or as a stage of illness in the course of recurrent unipolar depressive disorder; and <\/div>\n
[4] depressive disorders should be conceptualized as a continuum of severity.<\/div>\n

<\/p>\n

From the Psychopharmacology Research Program, Department of Psychiatry, University of California, San Diego, School of Medicine; the Psychiatric Service, VA Healthcare System, San Diego; Eli Lilly and Co., Indianapolis<\/font><\/strong>; Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh; and the Department of Psychiatry, University of Texas, Southwestern Medical Center, Dallas… Supported by an unrestricted research grant from Eli Lilly and Company<\/font><\/strong>; by the National Alliance for Research on Schizophrenia and Depression [Dr. Rapaport]; and by NIMH grants MH-30914, MH-49746, MH-80001 [Dr. Rapaport], MH-01908 [Dr. Yonkers], MH-30915 [Dr. Kupfer], MH-49115 and MH-30915 [Dr. Frank], and MH-53799 [Dr. Rush]. Dr. Schettler is a statistical consultant to Eli Lilly and Company<\/font><\/strong>.<\/em><\/div>\n<\/blockquote>\n
This article itself is somewhat dated. It’s the analysis of the placebo washout<\/em> four weeks before they gave the study drug [to eliminate placebo-responders?<\/em>]. It’s dated because it proposed an unique entity [miD<\/font><\/strong>] to include their MDD-lite<\/em><\/font><\/strong> patients. That would be hard to sell these days, though no one would question that there’s a large group of depressed people who don’t fit the MDD<\/font><\/strong> criteria [perhaps more that don’t than do]. Here’s the later efficacy report of Placebo versus Prozac®:<\/div>\n
\n
Randomized, Placebo-Controlled Trial of Fluoxetine for Acute Treatment of Minor Depressive Disorder<\/a><\/div>\n
by Lewis L. Judd, M.D.; Mark Hyman Rapaport, M.D.<\/font><\/strong>; Kimberly A. Yonkers, M.D.; A. John Rush, M.D.; Ellen Frank, Ph.D.; Michael E. Thase, M.D.; David J. Kupfer, M.D.; John M. Plewes, M.D.<\/font><\/strong>; Pamela J. Schettler, Ph.D.<\/font><\/strong>; and Gary Tollefson, M.D., Ph.D.<\/font><\/strong><\/div>\n
American Journal of Psychiatry<\/font><\/strong> 2004<\/font><\/strong> 161:1864-1871.
[full text on-line<\/a>]<\/div>\n

<\/p>\n

OBJECTIVE<\/font><\/strong><\/u>: Minor depressive disorder is both common and associated with significant psychosocial impairment. This study examined antidepressant treatment efficacy in a large group of patients with minor depressive disorder.  <\/div>\n
METHOD<\/font><\/strong><\/u>: One hundred sixty-two patients with minor depressive disorder were randomly assigned to receive fluoxetine or placebo in a 12-week, double-blind study; 73% [59 of 81] of the patients in each treatment group completed the study. Patients were evaluated weekly with standard depression rating instruments and measures of psychosocial impairment. Hypotheses were tested by last-observation-carried-forward analysis of variance [ANOVA] and confirmed by mixed [random-effects] regression analysis.<\/div>\n
RESULTS<\/font><\/strong><\/u>: At baseline, minor depressive disorder patients were mildly to moderately depressed, with a corresponding degree of functional impairment. Over 12 weeks of treatment, both ANOVA and mixed regression showed fluoxetine to be superior to placebo as indicated by significantly greater improvement of fluoxetine-treated patients in scores on the 30-item clinician-rated Inventory of Depressive Symptomatology, the 17-item and 21-item Hamilton Depression Rating Scale, the Beck Depression Inventory, and the Clinical Global Impression severity scale. Improvement in Global Assessment of Functioning Scale score was significantly greater for the fluoxetine group in mixed regression analysis only. Patients in both treatment groups reported a similar number and severity of adverse events during the 12-week treatment period.<\/div>\n
CONCLUSIONS<\/font><\/strong><\/u>: Clinicians frequently encounter minor depressive disorder either as a prodromal or residual phase of illness in major depressive disorder or as de novo minor depressive disorder episodes. Fluoxetine is significantly superior to placebo in reducing minor depressive disorder symptoms within a 12-week period. Improvement in psychosocial function with fluoxetine may take longer than 12 weeks.<\/div>\n

<\/p>\n

… and Eli Lilly & Co., Indianapolis [Drs. Plewes<\/font><\/strong><\/em>, Schettler<\/font><\/strong><\/em>, and Tollefson<\/font><\/strong>]… Supported in part by NIMH grants MH-30914, MH-49671, MH-30915, MH-53799, and MH-01648-01; the Roher Fund of the University of California, San Diego; and an unrestricted investigator-initiated contract from Eli Lilly & Co.<\/font><\/strong> <\/em><\/div>\n
<\/div>\n<\/blockquote>\n
Again, this post isn’t about vetting anything. But if it were, it would be hard to do because the data itself is behind the wall narrating various ANOVA calculations without any raw data to check. One thing one might do is express the numbers we do have in a more conventional way – change from baseline. One can do that with a bit of photoshop magic as below, melting the difference: <\/div>\n
<\/div>\n
Instead, they used the absolute scores and suceeded in making their Primary Efficacy Outcome [IDS-C] at 12 weeks [LOCF] by my calculations:<\/div>\n
<\/div>\n
My reason for looking at this clinical trial was historical. The 2002<\/font><\/strong> article mentions the Lilly funding in the acknowledgements, but doesn’t mention that two of the authors are full-time Lilly employees [John M. Plewes, M.D.<\/font><\/strong>; Gary D. Tollefson, M.D., Ph.D.<\/font><\/strong>]. They do acknowledge that Pamela J. Schettler, Ph.D.<\/font><\/strong> is a consultant for Lilly. By the 2004<\/font><\/strong> article, all three Lilly authors are mentioned ["… and Eli Lilly & Co., Indianapolis [Drs. Plewes<\/font><\/strong><\/em>, Schettler<\/font><\/strong><\/em>, and Tollefson<\/font><\/strong>]<\/em>"]. But in the 2013<\/font><\/strong> article, Pamela J. Schettler <\/font><\/strong>is labeled as being at Emory, though that must be a misprint. She is at University of California, San Diego<\/strong><\/a>.<\/strong> and not found in the Emory faculty search. Her affiliation with Lilly as a consultant or employee at Lilly is not addressed. Likewise, while the 2013<\/font><\/strong> article says that the "authors would like to thank John Plewes MD<\/font><\/strong> for his enthusiastic encouragement and support,"<\/em> they neither acknowledge his position at Lilly nor mention his history of similar studies. So even with the tightened conflict of interest rules, you’d have to look closely to see the influence of Lilly on this article:<\/div>\n
\n
  • \n
    Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials.<\/a><\/div>\n
    by Beasley CM Jr, Ball SG, Nilsson ME, Polzer J, Tauscher-Wisniewski S, Plewes J<\/font><\/strong>, and Acharya N.<\/div>\n
    J Clin Psychopharmacol. 2007 Dec;27[6]:682-6.<\/div>\n<\/li>\n
  • \n
    Meta-analysis of aggression and\/or hostility-related events in children and adolescents treated with fluoxetine compared with placebo.<\/a><\/div>\n
    by Tauscher-Wisniewski S, Nilsson M, Caldwell C, Plewes J,<\/font><\/strong> and Allen AJ.<\/div>\n
    J Child Adolesc Psychopharmacol. 2007 Oct;17[5]:713-8. Review.<\/div>\n<\/li>\n
  • \n
    Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder.<\/a><\/div>\n
    by Tauscher-Wisniewski S, Disch D, Plewes J<\/font><\/strong>, Ball S, and Beasley CM.<\/div>\n
    Psychol Med. 2007 Nov;37[11]:1585-93. Epub 2007 Jul 20. Review.<\/div>\n<\/li>\n
  • \n
    Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy in U.S. Hispanic and majority Caucasian patients.<\/a><\/div>\n
    by Lewis-Fern\u00e1ndez R, Blanco C, Mallinckrodt CH, Wohlreich MM, Watkin JG, and Plewes JM<\/font><\/strong>.<\/div>\n
    J Clin Psychiatry. 2006 Sep;67[9]:1379-90.<\/div>\n<\/li>\n
  • \n
    Duloxetine in the treatment of major depressive disorder: comparisons of safety and efficacy.<\/a><\/div>\n
    by Bailey RK, Mallinckrodt CH, Wohlreich MM, Watkin JG, and Plewes JM<\/font><\/strong>.<\/div>\n
    J Natl Med Assoc. 2006 Mar;98[3]:437-47.<\/div>\n<\/li>\n<\/blockquote>\n
    I would doubt that the 2004 article would be published in its current form. There’s just too little actual data by modern standards- at least I hope that’s true. <\/div>\n

    The timing of these articles is interesting. Prozac was FDA Approved in December 1987, and I suspect this study was a move to extend the indications from MDD<\/font><\/strong> to the ubiquitous miD<\/font><\/strong>, even weighing in on the side of inclusion of miD<\/font><\/strong> in the DSM-IV. Failing at that, the trial was tabled for a long time, missing in action. So why exhume it in 2002<\/font><\/strong> and 2004<\/font><\/strong>?. I speculated on two reasons: the coming of the DSM-5 and the eminent release of Lilly’s Cymbalta®. But maybe the authors just wanted another publication. It was unlikely related to Prozac® as that drug went off-patent in August 2001<\/font><\/strong>. By my reckoning, this study was a classic experimercial<\/font><\/strong><\/em><\/a> – a clinical trial done for marketing purposes rather than driven by any scientific goal – aimed at extending the target population for Prozac®. One of the many that litter our literature.<\/p>\n

    Now it’s twenty years later and this Clinical Trial has been revived in a form disconnected from its origins – one in a long line of articles that appear at regular intervals contesting the FDA Black Box Warning. A lot of them are some kind of retrospective like this one or the articles of Robert Gibbons extensively reviewed here [an anatomy of a deceit…<\/a>]. Some look at suicide statistics [NBER study<\/a>] or drug sales [Impact of Publicity Concerning Pediatric Suicidality Data on Physician Practice Patterns in the United States<\/a>]. Some even review media articles [News coverage of FDA warnings on pediatric antidepressant use and suicidality<\/a>]. Like this particular offering, they are often freebies – analyzing some existing dataset rather than doing an expensive new study. They often use some surrogate index or ancient data intended for some other purpose. Lilly has been involved in a lot of them. <\/p>\n

    While one might wonder why these articles keep coming, particularly from the Lilly\/Prozac® camp [since Prozac® has been off-patent for well over a decade and Cymbalta® goes off-patent in a month or so]. But the issue of suicidality associated with the antidepressants has taken on a meaning bigger than the basic question itself [which is already pretty big]. It has come to be a symbol for the concept that mental illness is biological and its treatment is exclusively with medications – an enterprise worth billions to the pharmaceutical industry and defines the role of many of the current generation of psychiatrists. <\/p>\n

    Looking at the Editorial Board<\/a> of the Journal of Psychiatric Research<\/font><\/strong> that published this article and adding in the authors of these papers, you’ll see a list of heavily published KOLs who remain committed to these exclusively biological·<\/font><\/strong>neuroscience·<\/font><\/strong>psychopharmacologic models that have predominated in psychiatry for the last twenty-five years [including the Senator Grassley veterans and APA presidents, past and present]. No one can predict what will happen if the current drive for data transparency eliminates these dodgy experimercials<\/font><\/strong><\/em><\/a> that plague our literature and loosens the control of the KOLs that have flourished in this age of the pharmaceutical·<\/font><\/strong>academic alliance. But whatever happens, it’s bound to be better than a steady diet of stories like the one told here. Neither the efficacy nor the safety of the current symptomatic medications come close to supporting a comprehensive strategy for the treatment of mental illness. That’s a self evident truth. Bickering about the frequency of akathisia, disinhibition, and suicidality with SSRIs is old news. It’s hard to imagine that any practitioner hasn’t seen it first hand – because it happens if you prescribe these drugs and follow the patients. It’s time for these wars of ideology to be put to rest and for a renewed focus on the care of the sick…<\/div>\n","protected":false},"excerpt":{"rendered":"

    Fluoxetine increases suicide ideation less than placebo during treatment of adults with minor depressive disorder by Steven J. Garlow, Becky Kinkead, Michael E. Thase , Lewis L. Judd, A. John Rush, Kimberly A. Yonkers , David J. Kupfer, Ellen Frank, Pamela J. Schettler, and Mark Hyman Rapaport Journal of Psychiatric Research 2013 47:1199-1203. Objective: Some […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_topic_count_hidden":0,"_bbp_reply_count_hidden":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[5],"tags":[],"class_list":["post-40992","post","type-post","status-publish","format-standard","hentry","category-opinion"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/40992","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=40992"}],"version-history":[{"count":76,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/40992\/revisions"}],"predecessor-version":[{"id":41069,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/40992\/revisions\/41069"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=40992"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=40992"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=40992"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}